Literature DB >> 29210320

Genetic variation in statin intolerance and a possible protective role for UGT1A1.

Maria Alice V Willrich1, Erin J Kaleta1, Sandra C Bryant2, Grant M Spears2, Laura J Train1, Sandra E Peterson1, Vanda A Lennon1, Stephen L Kopecky3, Linnea M Baudhuin1.   

Abstract

The etiology of statin intolerance is hypothesized to be due to genetic variants that impact statin disposition and clearance. We sought to determine whether genetic variants were associated to statin intolerance. The studied cohort consisted of hyperlipidemic participants (n = 90) clinically diagnosed with statin intolerance by a cardiologist and matched controls without statin intolerance. Creatine kinase activity, lipid profiles and genetic analyses were performed on genes involved in statin metabolism and included UGT1A1 and UGT1A3 sequencing and targeted analyses of CYP3A4*22, CYP3A5*3, SLCO1B1*5 and *1b, ABCB1 c.3435C>T, ABCG2 c.421C>A and GATM rs9806699. Although lipids were higher in cases, genetic variant minor allele frequencies were similar between cases and controls, except for UGT1A1*28, which was less prevalent in cases than controls.

Entities:  

Keywords:  ABC transporters; CYP3A; GATM; SLC transporters; UGT; genetic variants; myotoxicity; precision medicine; statin intolerance; statins

Mesh:

Substances:

Year:  2017        PMID: 29210320     DOI: 10.2217/pgs-2017-0146

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  2 in total

Review 1.  Potential of Phage Display Antibody Technology for Cardiovascular Disease Immunotherapy.

Authors:  Soo Ghee Yeoh; Jia Siang Sum; Jing Yi Lai; W Y Haniff W Isa; Theam Soon Lim
Journal:  J Cardiovasc Transl Res       Date:  2021-08-31       Impact factor: 3.216

2.  A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy.

Authors:  Saowalak Turongkaravee; Jiraphun Jittikoon; Thitiya Lukkunaprasit; Sermsiri Sangroongruangsri; Usa Chaikledkaew; Ammarin Thakkinstian
Journal:  Pharmacogenomics J       Date:  2021-02-19       Impact factor: 3.550

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.